Economic impact of disease progression in follicular non-Hodgkin lymphoma

References

• The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Altekruse S, Kosary C, Krapcho M, . SEER cancer statistics review, 1975-2007. Bethesda, MD: National Cancer Institute; 2010.
   Google Scholar
• Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20:75–88.
   PubMed Web of Science ®Google Scholar
• Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019–5026.
   PubMed Web of Science ®Google Scholar
• Italiano A, Thyss A. Follicular lymphoma: a therapeutic update. Bull Cancer 2005;92:E57–E64.
   PubMedGoogle Scholar
• Johnson PW, Rohatiner AZ, Whelan JS, . Patterns of survival in patients with recurrent follicular lymphoma:a 20-year study from a single center. J Clin Oncol 1995;13:140–147.
   PubMed Web of Science ®Google Scholar
• Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 2007;67:333–350.
   PubMed Web of Science ®Google Scholar
• Vose JM. Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach. Hematol Oncol 2006;24:47–55.
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, . The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064–3071.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, . Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725–3732.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, . CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–1423.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, . Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579–4586.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Radford J, Van Hoof A, . Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156–5164.
   PubMed Web of Science ®Google Scholar
• Maloney DG. What is the role of maintenance rituximab in follicular NHL? Oncology (Williston Park) 2008;22:20–26; discussion 26, 29, 33–24
   PubMed Web of Science ®Google Scholar
• Hochster H, Weller E, Gascoyne RD, . Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 2009;27:1607–1614.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti SB, . Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103:4416–4423.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial. Semin Oncol 2002;29:25–29.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE, . Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295–3301.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Van Glabbeke M, Giurgea L, . Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853–2858.
   PubMed Web of Science ®Google Scholar
• Salles GA, Seymour JF, Feugier P, . Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. J Clin Oncol 2010;28(15 Suppl.): Abstract 8004.
   Web of Science ®Google Scholar
• Salles GA, Catalano JV, Feugier P, . Rituximab maintenance for 2 years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study. Haematologica 2010;95(Suppl. 2): Abstract 0557.
   PubMed Web of Science ®Google Scholar
• Hornberger J, Reyes C, Lubeck D, Valente N. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma 2008;49:227–236.
   PubMed Web of Science ®Google Scholar
• Hayslip JW, Simpson KN. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission. Clin Lymphoma Myeloma 2008;8:166–170.
   PubMedGoogle Scholar
• Kutikova L, Bowman L, Chang S, Long SR, Arning M, Crown WH. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. Leuk Lymphoma 2006;47:1535–1544.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Brown ML, Riley GF, Potosky AL, Etzioni RD. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care 1999;37:1249–1259.
   PubMed Web of Science ®Google Scholar
• Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828–841.
   PubMed Web of Science ®Google Scholar
• Yabroff KR, Lamont EB, Mariotto A, . Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008;100:630–641.
   PubMed Web of Science ®Google Scholar
• Hayes AF, Cai L. Using heteroskedasticity-consistent standard error estimators in OLS regression:an introduction and software implementation. Behav Res Methods 2007;39:709–722.
   PubMed Web of Science ®Google Scholar
• Barnett A, Birnbaum H, Cremieux PY, Fendrick AM, Slavin M. The costs of cancer to a major employer in the United States:a case-control analysis. Am J Manag Care 2000;6:1243–1251.
   PubMed Web of Science ®Google Scholar
• Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002;40:IV-104–117.
   Web of Science ®Google Scholar
• Fireman BH, Quesenberry CP, Somkin CP, . Cost of care for cancer in a health maintenance organization. Health Care Financ Rev 1997;18:51–76.
   PubMed Web of Science ®Google Scholar
• Gallagher CJ, Gregory WM, Jones AE, . Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986;4:1470–1480.
   PubMed Web of Science ®Google Scholar
• Perea G, Altes A, Montoto S, . Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol 2005;16:1508–1513.
   PubMed Web of Science ®Google Scholar
• Montoto S, Lopez-Guillermo A, Ferrer A, . Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Ann Oncol 2002;13:523–530.
   PubMed Web of Science ®Google Scholar
• Gleeson M, Carolina R, Danese M, Knopf KB. Cost of follicular lymphoma (FL) in Medicare patients. J Clin Oncol 2008;26(Suppl.): Abstract 6634.
   Google Scholar